Photodynamic therapy in vulvar intraepithelial neoplasia (а review)
https://doi.org/10.37895/2071-8004-2021-25-4-51-59
Abstract
The authors discuss perspectives for applying photodynamic therapy (PDT) in patients with vulvar intraepithelial neoplasia (VIN); they also analyze domestic and foreign literature sources. Up to now, some experience on the treatment of background, precancerous conditions and vulvar cancer with PDT has been obtained. The authors describe application of various photosensitizers (5-aminolevulinic acid, hematoporphyrin, E6 chloride and others) as well as several techniques for photosensitizer administration and various parameters of photodynamic effect. PDT is a non-invasive modern curative option. This type of therapy has proven to be effective in many directions of medicine; it demonstrates a wide range of its potentials in antitumor, antimicrobial, antimycotic, antiviral, immunostimulating and many other effects. With PDT technique, one can preserve not only the function, but also the integrity of the organ; it gives an excellent cosmetic result as well as rapid recovery after the treatment. However, despite the low traumatic complication rate and low level of adverse reactions, data on PDT effectiveness are contradictory. In literature, there is a signififi cant range of set parameters for treatment and exposure modes from 50 to 350 J/cm2. Literature data demonstrate that PDT effectiveness in VIN treatment ranges from 30 to 95 %, while in some cases it reaches 100 %. So as to reliably assert PDT effectiveness in the discussed pathology, further research work is needed. This review analyzes other curative options, their advantages and disadvantages. The authors underline that effectiveness of other curative modalities is still low with a high rate of relapses.
About the Authors
V. S. LevchenkoRussian Federation
Levchenko Victoria – Oncologist-Gynecologist, 3rd Oncological Department
Nizhny Novgorod
N. A. Illarionova
Russian Federation
Illarionova Natalya – Oncologist-Gynecologist
Nizhny Novgorod
E. N. Koroleva
Russian Federation
Koroleva Elena – Oncologist-Gynecologist, 3rd oncological department
Nizhny Novgorod
S. V. Zinoviev
Russian Federation
Zinoviev Svyatoslav – Oncologist-Gynecologist, 3rd oncological department
Nizhny Novgorod
S. V. Gamayunov
Russian Federation
Gamayunov Sergey – Cand. Sc. (Med.)
Nizhny Novgorod
References
1. Van Dyne E.A., Henley S.J., Saraiya M., et al. Trends in human papillomavirus-associated cancers – United States, 1999–2015. MMWR Morb Mortal Wkly Rep. 2018; 67 (33): 918–924. DOI: 10.15585/mmwr.mm6733a2
2. Thuijs N., van Beurden M., Bruggink A., et al. Vulvar intraepithelial neoplasia: Incidence and long-term risk of vulvar squamous cell carcinoma. Int J Cancer. 2021; 148 (11): 2631– 2637. DOI: 10.1002/ijc.33198
3. Cohen P.A., Anderson L., Eva L., Scurry J. Clinical and molecular classifi cation of vulvar squamous pre-cancers. Int J Gynecol Cancer. 2019; 29 (4): 821–828. DOI: 10.1136/ijgc-2018-000135
4. Wohlmuth C., Wohlmuth-Wieser I. Vulvar malignancies: An interdisciplinary perspective. J Dtsch Dermatol Ges. 2019; 17 (12): 1257–1276. DOI: 10.1111/ddg.13995
5. zur Hausen H. Papillomaviruses in the causation of human cancers – a brief historical account. Virology. 2009; 384 (2): 260–265. DOI: 10.1016/j.virol.2008.11.046
6. Novikova E.G., Chulkova O.V. Peculiarities of clinical course of vulva background and cancer in young people. Akusherstvo i ginekologiya: novosti, mneniya, obuchenie (Obstetrics and Gynecology: News, Opinions, Training). 2017; 1 (15): 83–88. [In Russ.].
7. Hoang L.N., Park K.J., Soslow R.A., Murali R. Squamous precursor lesions of the vulva: Current classifi cation and diagnostic challenges. Pathology. 2016; 48(4): 291–302. DOI: 10.1016/j.pathol.2016.02.015
8. de Sanjosé S., Alemany L., Ordi J., et al. Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013; 49 (16): 3450–3461. DOI: 10.1016/j.ejca.2013.06.033
9. Gargano J.W., Wilkinson E.J., Unger E.R., et al. Prevalence of human papillomavirus (HPV) types in invasive vulvar cancers and VIN3 in the United States before vaccine introduction. J Low Genit Tract Dis. 2012; 16 (4): 471-479. DOI: 10.1097/LGT.0b013e3182472947
10. Faber M.T., Sand F.L., Albieri V., et al. Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva. Int J Cancer. 2017; 141 (6): 1161–1169. DOI: 10.1002/ijc.30821
11. Disai F.J., Krisman U.T. Clinical oncogynecology. Moscow: Publishing house “ Prakticheskaya meditsina”; 2012. [In Russ.].
12. Lawrie T.A., Nordin A., Chakrabarti M., et al. Medical and surgical interventions for the treatment of usual-type vulval intraepithelial neoplasia. Cochrane Database Syst Rev. 2016; 2016 (1): CD011837. DOI: 10.1002/14651858.CD011837.pub2
13. van Esch E.M., Dam M.C., Osse M.E., et al. Clinical characteristics associated with development of recurrence and progression in usual-type vulvar intraepithelial neoplasia. Int J Gynecol Cancer 2013; 23 (8): 1476–1483. DOI: 10.1097/IGC.0b013e3182a57fd6
14. Fehr M.K., Baumann M., Mueller M., et al. Disease progression and recurrence in women treated for vulvovaginal intraepithelial neoplasia. J Gynecologic Oncol. 2013; 24 (3): 236–241. DOI: 10.3802/jgo.2013.24.3.236
15. Mahmoud G., Jedelska J., Strehlow B., Bakowsky U. Bipolar tetraether lipids derived from thermoacidophilic archaeon Sulfolobus acidocaldarius for membrane stabilization of chlorin e6 based liposomes for photodynamic therapy. Eur J Pharm Biopharm. 2015; 95 (Pt A): 88–98. DOI: 10.1016/j.ejpb.2015.04.009
16. Morikawa K., Suda G. Sakamoto N. Viral life cycle of hepatitis B virus: Host factors and druggable targets. Hepatol Res. 2016; 46 (9): 871–877. DOI: 10.1111/hepr.12650
17. De Clercq E., Li G. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev. 2016; 29 (3): 695–747. DOI: 10.1128/CMR.00102-15
18. Sobotta L., Skupin-Mrugalska P., Mielcarek J., et al. Photosensitizers mediated photodynamic inactivation against virus particles. Mini-Rev Med Chem. 2015; 15 (6): 503–521. DOI: 10.2174/1389557515666150415151505
19. Janouskova O., Rakusan J., Karaskova M., Holada K. Photodynamic inactivation of prions by disulfonated hydroxyaluminium phthalocyanine. J Gen Virol. 2012; 93 (P 11): 2512– 2517. DOI: 10.1099/vir.0.044727-0
20. Wainwright M. Photoinactivation of viruses. Photochem Photobiol Sci. 2004; 3 (5): 406–411. DOI: 10.1039/b311903n
21. Costa L., Faustino M.A.F., Neves M.G., et al. Photodynamic inactivation of mammalian viruses and bacteriophages. Viruses. 2012; 4 (7): 1034–1074. DOI: 10.3390/v4071034
22. Martin-Hirsch P.L., Whitehurst C., Buckley C.H., et al. Photodynamic treatment for lower genital tract intraepithelial neoplasia. Lancet. 1998; 351 (9113): 1403. DOI: 10.1016/s0140-6736(98)24019-0
23. Kurwa H.A., Barlow R.J., Neill S. Single-episode photodynamic therapy and vulval intraepithelial neoplasia type III resistant to conventional therapy. Br J Dermatol. 2000; 143 (5): 1040–1042. DOI: 10.1046/j.1365-2133.2000.03785.x
24. Hillemanns P., Untch M., Dannecker C., et al. Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid. Int J Cancer. 2000; 85 (5): 649–653. DOI: 10.1002/(sici)1097-0215(20000301)85:5<649::aid-ijc9>3.0.co;2-e
25. Fehr M.K., Hornung R., Schwarz V.A., et al. Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevulinic acid. Gynecol Oncol. 2001; 80 (1): 62–66. DOI: 10.1006/gyno.2000.6028
26. Abdel-Hady E.S., Martin-Hirsch P., Duggan-Keen M., et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 2001; 61 (1): 192–196.
27. Campbell S.M., Gould D.J., Salter L., et al. Photodynamic therapy using meta-tetrahydroxyphenylchlorin (Foscan) for the treatment of vulval intraepithelial neoplasia. Br J Dermatol. 2004; 151 (5): 1076–1080. DOI: 10.1111/j.1365-2133.2004.06197.x
28. Choi M.C., Kim M.S., Lee G.H., et al. Photodynamic therapy for premalignant lesions of the vulva and vagina: A long-term follow-up study. Lasers Surg Med. 2015; 47 (7): 566–570. DOI: 10.1002/lsm.22384
29. Zhang R., Wang L. Photodynamic therapy for treatment of usual-type vulvar intraepithelial neoplasia: A case report and literature review. J Int Med Res. 2019; 47 (8): 4019– 4026. DOI: 10.1177/0300060519862940
30. Chulkova O.V., Novikova E.G., Sokolov V.V. Diagnostics and treatment of vulva background and precancerous conditions Practical Oncology. 2006; 7 (4): 197–204. [In Russ.].
31. Malandin A.G. Photodynamic therapy for treating background and cancerous conditions in female external genitalia. Zhurnal rossiyskogo obshchestva akusherov i ginekologov. 2009; (1): 32–38. [In Russ.].
32. Filonenko E.V., Serova L.G. Clinical observations of effective photodynamic therapy in a patient with severe vulva dysplasia. Photodynamic therapy and photodyagnosis . 2014; 3 (4): 31–33 [In Russ.].
33. Dunaevskaya V.V., Tatarchuk T.F., Zakharenko N.F., et al. Photodynamic therapy in the treatment of patients with vulvar premalignant diseases. First experience of its use in Ukraine. Reproductive Endocrinology. 2020; (4): 22–26. DOI: 10.18370/2309-4117.2020.54.22-26
Review
For citations:
Levchenko V.S., Illarionova N.A., Koroleva E.N., Zinoviev S.V., Gamayunov S.V. Photodynamic therapy in vulvar intraepithelial neoplasia (а review). Laser Medicine. 2021;25(4):51-59. (In Russ.) https://doi.org/10.37895/2071-8004-2021-25-4-51-59